PROBLEM TO BE SOLVED: To provide a crystalline form of a compound as a mineralcorticoid receptor antagonist and a preparation method thereof as well as an application in the preparation of a medicament in which the crystalline form of a compound treats and/or prevents nephropathy or cardiovascular disease.SOLUTION: The present invention belongs to the field of pharmaceutical technology, and relates to a crystalline form of a compound as a mineralocorticoid receptor antagonist and a preparation method thereof, specifically, a preparation method of a compound represented by the formula (1) 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile, a crystalline form thereof, a method for preparing the crystalline form as well as an application in the preparation of a medicament in which the crystalline form treats and/or prevents nephropathy or cardiovascular disease.SELECTED DRAWING: NoneCOPYRIGHT: (C)2020,JPO&INPIT【課題】本発明は医薬品技術の分野に属し、具体的にはミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法並びに化合物の結晶形が腎障害または心血管疾患を治療及び／又は予防する薬物の調製における応用に関する。【解決手段】本発明は医薬品技術の分野に属し、ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法を関し、具体的には式（１）で示される化合物２－クロロ－４－［（３Ｓ，３ａＲ）－３－シクロペンチル－７－（４－ヒドロキシピペリジン－１－カルボニル）－３，３ａ，４，５－テトラヒドロ－２Ｈ－ピラゾロ［３，４－ｆ］キノリン－２－イル］ベンゾニトリルの調製方法、その結晶形、結晶形の調製方法並びにその結晶形が腎障害または心血管疾患を治療及び／又は予防する薬物の調製における応用に関する。【選択図】なし
